In October 2024, in collaboration with the Swiss Cancer Group, formerly the Swiss Cancer Group for Clinical Cancer Research (SAKK), the Company initiated and dosed our first patient in the INVINCIBLE-4 Study. In September 2025, the Company paused new patient enrollment to revise the dosing regimen for patients receiving INT230-6 in cohort A due to some patients in Cohort A experiencing localized skin irritation near the tumor site. The Company plans to file a protocol amendment for this revision in dosing i ...

Financial Performance - Net income for the community banking segment increased to $6.9 million for Q3 2025, up from $4.7 million in Q3 2024, representing a 46.8% increase[155] - Net interest income rose by $2.4 million to $14.6 million in Q3 2025 compared to $12.3 million in Q3 2024, a growth of 19.5%[155] - The mortgage banking segment reported a net income of $948,000 in Q3 2025, a turnaround from a net loss of $50,000 in Q3 2024[158] - Net income for the nine months ended September 30, 2025, totaled $17.8 million, up from $11.7 million for the same period in 2024[176] - Net income for the nine months ended September 30, 2025, increased to $18.7 million, up from $13.5 million in the same period of 2024, representing a growth of 38.8%[183] - Earnings per share (EPS) for the nine months ended September 30, 2025, rose to $1.04, compared to $0.72 for the same period in 2024, reflecting an increase of 44.4%[183] Income and Expenses - Total noninterest income decreased by $250,000, or 1.1%, to $22.3 million, primarily due to a $19.9 million, or 3.6%, decrease in total loan origination volume[172] - Total noninterest income decreased by $6.6 million, or 9.3%, to $63.7 million for the nine months ended September 30, 2025, compared to $70.3 million for the same period in 2024[194] - Total noninterest expenses decreased by $1.1 million, or 3.8%, to $27.5 million for the three months ended September 30, 2025, compared to $28.6 million for the same period in 2024[173] - Total noninterest expenses decreased by $4.2 million, or 4.8%, to $82.2 million for the nine months ended September 30, 2025, compared to $86.4 million for the same period in 2024[195] - Compensation and employee benefits expense decreased by $290,000 to $5.0 million in Q3 2025, primarily due to lower health insurance claims[157] - Total compensation and employee benefits decreased by $3.5 million, or 7.3%, to $44.1 million for the nine months ended September 30, 2025, primarily due to reduced employee headcount[181] Asset Quality and Credit Losses - The provision for credit losses was negative $269,000 for the three months ended September 30, 2025, compared to negative $377,000 for the same period in 2024, reflecting improved risk factors[170] - The provision for credit losses was a negative $836,000 for the nine months ended September 30, 2025, compared to a negative provision of $535,000 in the same period of 2024, indicating improved asset quality[192] - Total nonperforming assets decreased to $6.1 million at September 30, 2025, from $6.2 million at December 31, 2024, with total non-accrual loans to total loans remaining stable at 0.35%[212] - The allowance for credit losses decreased to $17.7 million at September 30, 2025, with a negative provision of $599,000 for the nine months ended September 30, 2025[204] - Past due loans decreased by $6.6 million, or 43.7%, to $8.5 million at September 30, 2025, from $15.1 million at December 31, 2024[221] Loan Originations and Mortgage Banking - Total mortgage loan originations decreased by $19.3 million, or 3.5%, to $539.4 million in Q3 2025 from $558.7 million in Q3 2024[158] - Mortgage banking noninterest income decreased by $7.4 million, or 11.1%, to $59.4 million for the nine months ended September 30, 2025, due to a decrease in loan production volume[179] - The company originated $1.52 billion in mortgage loans held for sale during the nine months ended September 30, 2025, a decrease of $162.0 million, or 9.7%, from the previous year[179] - Mortgage banking income declined by $7.0 million, or 10.6%, primarily due to a $150.1 million decrease in loan origination volumes, which fell to $1.51 billion[194] Interest Income and Margin - Net interest margin improved to 2.76% in Q3 2025 compared to 2.14% in Q3 2024[165] - Net interest income increased by $7.7 million, or 23.1%, to $41.0 million during the nine months ended September 30, 2025, compared to $33.3 million in 2024[190] - The average yield on loans increased by 22 basis points, contributing to a $903,000 increase in interest income on loans, despite a $48.3 million decrease in average loans receivable[191] - Interest income on loans rose by $35,000, or 0.1%, to $26.6 million, driven by a 19 basis point increase in average yield, despite a $61.0 million decrease in average loans receivable[168] Regulatory and Capital Position - As of September 30, 2025, WaterStone Bank exceeded all regulatory capital requirements and is considered "well capitalized" under regulatory guidelines[241] - Shareholders' equity increased by $6.4 million to $345.5 million at September 30, 2025, primarily due to increases in net income and the fair value of the securities portfolio[210] - The Company had approximately $365.8 million of uninsured deposits for approximately 1,462 customers as of September 30, 2025[237] Interest Rate Risk Management - WaterStone Bank's interest rate risk management strategy includes emphasizing variable rate loans and reducing the expected average life of the investment portfolio[245] - The most recent income simulation indicates that a 100 basis point increase in interest rates would decrease forecast net interest income over the next 12 months by 3.60%[249] - Conversely, a 100 basis point decrease in interest rates would increase net interest income by 1.01%[249] - The Asset/Liability Committee meets at least weekly to review asset/liability policies and interest rate risk position[244] - The bank's interest rate risk exposure is regularly monitored and evaluated quarterly[246]

Revenue Growth - Total revenue for Q3 2025 increased by 19% to $60.2 million, with product revenue reaching a record $52.7 million, up 15% year-over-year[1][3][4] - Government contract revenue for Q3 2025 was $7.5 million, a 63% increase from $4.6 million in the prior year, driven by R&D activities related to the INTERCEPT RBC program[5][3] - Hospital demand for INTERCEPT fibrinogen complex (IFC) in the U.S. rose significantly, with Q3 sales totaling $3.9 million, up from $2.3 million in the prior year, reflecting a 110% increase in volumes[3][4] - The company raised its full-year 2025 product revenue guidance to a range of $202 million to $204 million, indicating a growth of 12% to 13% from 2024[1][15] - Product revenue for Q3 2025 reached $52.698 million, a 15% increase from $46.017 million in Q3 2024[30] Profitability and Expenses - Non-GAAP adjusted EBITDA for Q3 2025 was $5.0 million, compared to $4.4 million in the same period last year, with a positive adjusted EBITDA expected for the full year[11][12] - Product gross profit for Q3 2025 was $28.1 million, a 7% increase year-over-year, while product gross margin decreased to 53.4% from 56.9% due to inflationary pressures and higher production costs[6][3] - Total operating expenses for Q3 2025 were $34.4 million, reflecting an 8% increase from $31.8 million in the prior year[7][3] - Selling, general and administrative expenses for Q3 2025 totaled $18.618 million, compared to $17.786 million in Q3 2024, reflecting a 5% increase[30] Research and Development - R&D expenses for Q3 2025 increased to $15.8 million, driven by higher government contract costs and enrollment in the Phase 3 RedeS trial[8][3] - The company completed enrollment in the U.S. RedeS trial, with results expected in the second half of 2026, further supporting its product development efforts[3][4] - Research and development expenses for Q3 2025 were $15.825 million, up from $14.013 million in Q3 2024, indicating a 13% increase[30] Financial Position - Cash, cash equivalents, and short-term investments stood at $78.5 million as of September 30, 2025, with $1.9 million generated from operations during the quarter[13][14] - Total current assets as of September 30, 2025, were $167.127 million, up from $152.022 million at the end of 2024, indicating a 10% increase[32] - Total liabilities as of September 30, 2025, were $152.981 million, compared to $144.021 million at the end of 2024, reflecting a 6% increase[32] Net Loss - Net loss attributable to Cerus Corporation for Q3 2025 was $19 thousand, a significant improvement from a net loss of $2.934 million in Q3 2024[30]

Financial Performance - Q3 2025 sales reached $61.0 million, an increase of 11% year-over-year, with organic growth of 12%[4] - Adjusted operating income for Q3 2025 was $16.9 million, a 29% increase compared to the previous year[4] - Net income for the three months ended September 30, 2025, was $17,362,000, compared to $11,141,000 for the same period in 2024, marking a 55.7% increase[20] - Adjusted EBITDA for the three months ended September 30, 2025, was $19,238,000, reflecting a 22% increase compared to $15,776,000 in the same period of 2024[27] - Basic earnings per share for the three months ended September 30, 2025, was $0.77, up from $0.50 in the same period of 2024[20] - The company reported an operating margin of 33% for the three months ended September 30, 2025, down from 27% in the previous year[24] Sales and Growth - Grafts and Shunts sales grew by 23% and 18% respectively, with Artegraft experiencing a 33% growth due to international launch[4] - The company provided Q4 2025 sales guidance of $61.8 million to $63.8 million, representing a 13% increase year-over-year[5] - Full year 2025 sales guidance is set at $247 million to $249 million, also reflecting a 13% increase[5] - The company projects full-year net sales guidance for 2025 at $248,000,000, with an adjusted projected net sales increase of 13% for the year[26] - The Americas accounted for 64% of net sales in Q3 2025, with sales of $39,218,000, up from $35,802,000 in Q3 2024[21] Profitability and Margins - Adjusted gross margin improved to 70.8%, up from 67.8% in Q3 2024, driven by higher average selling prices and manufacturing efficiencies[4] - Gross profit for the three months ended September 30, 2025, was $45,955,000, representing a gross margin of 75.3%[22] - Total operating expenses for the three months ended September 30, 2025, were $25,643,000, compared to $24,030,000 in Q3 2024[20] - Cash dividends declared per common share increased to $0.20 for the three months ended September 30, 2025, compared to $0.16 in the same period of 2024[20] Financial Position - Cash reserves increased by $23.6 million sequentially to $343.1 million[8] - Total assets increased to $598,006,900 from $551,817,000[19] - Current assets totaled $452,025,400, with cash and cash equivalents at $254,949[19] - Total liabilities amounted to $219,146,221, up from $155,181,717[19] - Accounts receivable net reached $324,163,630, reflecting a significant increase[19] - Goodwill remained stable at $65,945,656, indicating no impairment[19] - Total current liabilities were $332,873,060, with accounts payable at $346,565[19] - Retained earnings stood at $173,670,145, showing a positive growth trend[19] - The company reported a total stockholders' equity of $378,923,333, up from $372,929,900[19] - The net inventory and other deferred costs were reported at $70,793,936[19] - The company has maintained a strong cash position with short-term marketable securities at $317,561,127[19] Shareholder Actions - The company announced a quarterly dividend of $0.20 per share, payable on December 4, 2025[6] - A share repurchase program of up to $75.0 million was authorized, set to conclude on February 17, 2026[7] Investment and Growth Strategy - The company is investing in its sales force, new international offices, and regulatory approvals to support growth[5]

Company Overview - The company is a non-diversified, externally managed specialty finance company focused on lending to middle-market companies, regulated as a BDC under the Investment Company Act of 1940[359]. - The company is not a subsidiary of Morgan Stanley and has no obligation for financial support from Morgan Stanley[359]. - The company aims to maintain its qualification as a BDC and as a regulated investment company under the Internal Revenue Code[367]. Investment Strategy - The investment objective is to achieve attractive risk-adjusted returns primarily through current income from senior secured term loans issued by U.S. middle-market companies, typically generating annual EBITDA between $15 million and $200 million[360]. - Revenue is primarily generated from interest income on debt investments, with additional income from dividends, capital gains, and various fees, reflecting a focus on directly originated senior secured term loans[362][365]. - The company expects its debt investments to have a stated term of five to eight years, typically bearing interest at a floating rate based on benchmarks like SOFR[361]. - The level of investment activity can vary significantly based on factors such as available debt for middle-market companies and the general economic environment[364]. Financial Performance - Total investment income for Q3 2025 was $99,722, a decrease of 9.4% from $109,752 in Q3 2024[383]. - Net investment income after taxes for Q3 2025 was $43,730, down 25.5% from $58,729 in Q3 2024[383]. - The total portfolio value as of September 30, 2025, was $3,837,722, an increase from $3,662,618 at the end of Q3 2024[377]. - The weighted average yield on debt and income-producing investments at cost was 9.7% as of September 30, 2025, compared to 10.4% at the end of 2024[377]. - New investment commitments in portfolio companies totaled $183,049 for Q3 2025, significantly lower than $455,365 in Q3 2024[377]. - Total investment income decreased from $109,752 to $99,722 for the three months ended September 30, 2025, and from $313,041 to $300,690 for the nine months ended September 30, 2025, primarily due to declining base rates and repricing on the existing portfolio[385]. - Weighted average yield at cost decreased to 9.7% as of September 30, 2025, from 11.0% as of September 30, 2024[385]. Portfolio and Investment Metrics - The number of portfolio companies increased to 218 as of September 30, 2025, from 208 at the end of 2024[377]. - The average position size of investments decreased to $17.3 million as of September 30, 2025, from $18.2 million at the end of 2024[377]. - The percentage of debt investments with one or more financial covenants was 59.1% as of September 30, 2025, down from 64.6% at the end of 2024[377]. - The percentage of performing debt bearing a floating rate at fair value remained stable at 99.6% as of September 30, 2025[377]. - Approximately 99.6% of the Company's debt investments were at floating rates as of September 30, 2025[422]. Expenses and Liabilities - Operating expenses include investment advisory fees, administrative costs, and other operational expenses, with expectations for general and administrative expenses to remain stable or decline during asset growth periods[367][368]. - Interest and other financing expenses increased to $33,903 for the three months ended September 30, 2025, from $33,153 for the same period in 2024, and to $102,788 for the nine months ended September 30, 2025, from $89,715 in 2024[388]. - Average borrowings outstanding increased to $2,021,437 for the three months ended September 30, 2025, compared to $1,799,879 for the same period in 2024[388]. - As of September 30, 2025, the total outstanding debt obligations were $3,484,000, with $2,078,120 outstanding and $1,396,105 unused[408]. Shareholder Returns and Distributions - Total distributions declared for the nine months ended September 30, 2025, amounted to $1.50 per share, compared to $1.60 per share for the same period in 2024[402]. - The Company declared a distribution of $0.50 per share on November 4, 2025, payable on or around January 23, 2026[412]. - The company entered into a share repurchase plan to acquire up to $100 million of its Common Stock at prices below its net asset value per share[404]. - Total shares repurchased under the Original Company 10b5-1 Plan from January 1 to September 30, 2025, amounted to 1,699,876 shares[405]. - The average price paid per share for repurchases in March 2025 was $20.38, with a total of 459,142 shares purchased[405]. IPO and Management Fees - The company closed its IPO on January 26, 2024, issuing 5,000,000 shares at a public offering price of $20.67 per share, resulting in net cash proceeds of approximately $97.1 million[396]. - The management fee waiver expired on January 24, 2025, leading to an increase in base management fees to $9,628 for the three months ended September 30, 2025, from $6,825 in 2024[389]. Market Sensitivity - A hypothetical increase of 300 basis points in interest rates would result in a net income increase of $72,523,000[422]. - The net realized gain for Q3 2025 was $26, compared to a loss of $10,965 in Q3 2024[383]. - Net realized gains were $26 and $666 for the three and nine months ended September 30, 2025, respectively, compared to net realized losses of $10,965 and $16,482 for the same periods in 2024[392].

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________ FORM 10-Q ________________________ (Mark One) or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission File Number 001-40860 ________________________ Olaplex Holdings, Inc. (Exact name of registrant as specified in its charter) ________________________ Delaware 87-1242679 (State or other juri ...

Financial Performance - Revenue for Q3 2025 was $41.6 million, a 39.7% decrease year-over-year from $69.0 million in Q3 2024[5] - Net loss for Q3 2025 was $(45.1) million, compared to a net loss of $(172.5) million in Q3 2024[7] - Adjusted EBITDA for Q3 2025 was $(10.8) million, down from $16.2 million in Q3 2024[7] - Revenue for the first nine months of 2025 was $135.9 million, a 32.9% decrease from $202.6 million in the same period of 2024[8] - Full year 2025 revenue guidance is approximately $185.0 million, excluding potential revenue from high-volume CleanCap orders and new acquisitions[3] Revenue Segments - Nucleic Acid Production revenue decreased by 52.9% year-over-year to $25.4 million, primarily due to a lack of high-volume CleanCap orders[9] - Biologics Safety Testing revenue increased by 7.2% year-over-year to $16.3 million, driven by strength in nearly all product lines[9] Future Outlook - The company expects TriLink to deliver double-digit sequential revenue growth in Q4 2025[2] - Maravai expects TriLink to achieve double-digit sequential revenue growth in Q4 2025, indicating a positive outlook for the upcoming quarter[25] - The company anticipates delivering attractive financial results in both Q4 2025 and 2026, reflecting confidence in its operational strategies[25] - The company aims to strengthen its position to deliver attractive financial results in 2026[3] Loss and Adjustments - For the three months ended September 30, 2025, Maravai reported a net loss attributable to the company of $25.6 million, compared to a net loss of $97.1 million for the same period in 2024[15] - The adjusted net loss (non-GAAP) for the three months ended September 30, 2025, was $21.3 million, while for the nine months ended September 30, 2025, it was $62.6 million[15] - The adjusted fully diluted loss per share (non-GAAP) for the three months ended September 30, 2025, was $0.08, compared to $0.01 for the same period in 2024[15] - The company incurred $9.1 million in stock-based compensation for the three months ended September 30, 2025, compared to $13.1 million for the same period in 2024[15] Organizational Changes and Costs - Organizational restructuring and operating cost reduction initiatives are on track[1] - Maravai's leadership transition in June 2025 resulted in executive leadership transition costs of $2.0 million for the nine months ended September 30, 2025[17] - Maravai's retention payment expenses related to acquisitions totaled $2.9 million for the three months ended September 30, 2024[16] Market Position and Risks - The company is focused on expanding its market presence in the fields of nucleic acid synthesis and biologics safety testing, serving leading biopharmaceutical and vaccine companies[23] - Maravai faces competition from larger life science, pharmaceutical, and biotechnology companies that may develop superior products, potentially rendering Maravai's offerings obsolete[27] - The company is dependent on a limited number of customers for a significant portion of its revenue, which poses risks to maintaining these relationships[27] - There are risks related to the potential failure of Maravai's products to meet quality standards and market acceptance[27] - The company is exposed to geopolitical instability and natural disasters, which could adversely affect operations[27] - Maravai's ability to generate sufficient cash flow to service its existing debt obligations is critical, given its current level of indebtedness[27] - The company may face challenges in managing strategic acquisitions and organic growth opportunities effectively[27] - Risks associated with compliance to intellectual property obligations and potential infringement claims could impact operations[27] Financial Controls and Impairments - Maravai's ability to maintain effective internal controls over financial reporting is essential for timely remediation of material weaknesses[28] - The potential for future impairment of goodwill and intangible assets could negatively affect Maravai's financial position[28] - The company recognized a goodwill impairment of $154.2 million for its Nucleic Acid Production segment during the nine months ended September 30, 2024[17] - Maravai's organizational structure includes a Tax Receivable Agreement that may require substantial future cash payments, impacting financial flexibility[28]

Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Johanna Schmitt Mark Stoutenberg Media Relations Investor Relations Akamai Technologies Akamai Technologies Revenue: Revenue was $1.055 billion, a 5% increase over third quarter 2024 revenue of $1.005 billion and a 4% increase when adjusted for foreign exchange.* Revenue by solution: Cloud Infrastructure Services** revenue of $81 million, up 39% year-over-year and when adjusted for foreign exchange* GAAP net income per diluted share of $0.97, up 155% year-over-ye ...

Financial Performance - Total net revenue for the three months ended September 30, 2025, was $961.6 million, representing a 38% increase compared to the same period in 2024 [296]. - Total fee-based revenue reached a record of $408.7 million for the third quarter of 2025, a year-over-year increase of 50% [296]. - Net income for the three months ended September 30, 2025, was $139.4 million, a 129% increase compared to $60.7 million in the same period of 2024 [297]. - Adjusted net revenue for the three months ended September 30, 2025, was $949.6 million, up from $689.4 million in 2024 [314]. - Adjusted EBITDA for Q3 2025 was $276,881, up 48.7% from $186,237 in Q3 2024 [329]. - Total net revenue for the Lending segment was $493.4 million for the three months ended September 30, 2025, a 25% increase from $396.2 million in 2024 [431]. - Total net revenue for the reportable segments reached $1,027.6 million for the three months ended September 30, 2025, reflecting a 39% increase from $737.1 million in 2024 [430]. Lending Segment - The Lending Segment includes personal loans, student loans, and home loans, with loan sizes generally ranging from $5,000 to $100,000 for personal loans and $75,000 to $806,500 for home loans [276][278]. - The Lending segment contribution profit was $261.6 million for the three months ended September 30, 2025, with a contribution margin of 53% [302]. - Lending products origination volume increased by 57% and 62% for the three and nine months ended September 30, 2025, respectively, with over $4.6 billion and $11.1 billion sold or transferred through the Loan Platform Business [303]. - Personal loan origination volume increased by $2.6 billion, or 53%, for the three months ended September 30, 2025, compared to the same period in 2024 [450]. - Total personal loan origination volume increased by 53% and 62% for the three and nine months ended September 30, 2025, respectively, compared to the same periods in 2024, with increases of $3.4 billion and $7.4 billion attributed to loans originated for third parties [454]. Member Growth and Engagement - Total members reached over 12.6 million as of September 30, 2025, reflecting a 35% year-over-year increase [300]. - The company aims to create a "Financial Services Productivity Loop," where positive member experiences lead to new product adoption and increased profitability [267]. - The company has developed a member home experience within its digital application, which has driven new product adoption and increased member engagement [261]. Technology and Innovation - The company operates through three reportable segments: Lending, Technology Platform, and Financial Services, each contributing to its overall growth strategy [273]. - The company has made strategic acquisitions to enhance its technology platform capabilities, aiming to deepen its participation in the digital financial services ecosystem [260]. - The company continues to diversify its Technology Platform client base through partnerships with various U.S. consumer brands [304]. - New product innovations include self-serve global remittance services and a return to crypto investing, expanding the company's offerings in international money transfers and cryptocurrency [309]. Financial Services Performance - Financial Services segment contribution profit improved significantly to $225.6 million and $562.1 million for the three and nine months ended September 30, 2025, compared to $99.8 million and $192.2 million in 2024, with total net revenue increasing by 76% and 92% respectively [305]. - Referral fees accounted for 13% of total Financial Services noninterest income for the nine months ended September 30, 2025 [299]. - Interchange fees represented 15% of total Financial Services noninterest income for the nine months ended September 30, 2025 [299]. Credit and Risk Management - The provision for credit losses increased by 53% year-over-year to $9,199,000 in Q3 2025 [372]. - The allowance for credit losses increased to $50.6 million as of September 30, 2025, with a ratio of allowance for credit losses to total loans outstanding at 3.33% [403]. - Annualized net charge-off rates for personal loans were 2.60%, remaining below the weighted average default rate of 4.33% [371]. - The total net charge-off ratio for the three months ended September 30, 2025, was 1.90%, a decrease of 64 basis points compared to the same period in 2024 [411]. Operational Expenses - Total noninterest expense for Q3 2025 was $803,850,000, a 28% increase from $627,253,000 in Q3 2024 [372]. - Sales and marketing expenses rose by $72.0 million, or 33%, for the three months ended September 30, 2025, driven by higher advertising and marketing expenditures [419]. - General and administrative expenses increased by $39.5 million, or 27%, for the three months ended September 30, 2025, attributed to higher employee compensation and benefits [423].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-39603 REVELATION BIOSCIENCES, INC. (Exact Name of Registrant as Specified in its Charter) | Delaware | 84-3898466 | | --- | --- | | ( State or other jurisdicti ...